TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.

• Material Type: 博士論文
• Title: TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.
• Author/Editor: Kaya, Daisuke; Kaji, Kosuke; Tsuji, Yuki; Yamashita, Satoko; Kitagawa, Koh; Ozutsumi, Takahiro; Fujinaga, Yukihisa; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
• Author Heading: Kaya, Daisuke; Kaji, Kosuke; Tsuji, Yuki; Yamashita, Satoko; Kitagawa, Koh; Ozutsumi, Takahiro; Fujinaga, Yukihisa; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
• Publication, Distribution, etc.: MDPI
• Publication Date: 2019-09-26
• Publication Date (W3CDTF): 2019-09-26
• Alternative Title: TGR5活性化はアナグリプチンによる糖尿病ラットに対する肝線維化抑制効果を増強する
• Periodical title: Cells
• No. or year of volume/issue: 8 10
• Volume: 8
• Issue: 10
• Pages: Article No.1153-
• ISSN (Periodical Title): ISSN : 2073-4409
• Degree grantor/type: 奈良県立医科大学
• Date Granted: 2021-03-15
• Dissertation Number: 甲第766号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: dipeptidyl peptidase-4 inhibitors; hepatic stellate cells; oleanolic acid; Takeda G protein-coupled receptor 5
• Target Audience: 一般
• Note (General): type:Thesis; Hyperglycemia and hyperinsulinemia activate the proliferative potential of hepatic stellate cells (HSCs) and promote hepatic fibrosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors, antidiabetic agents, reportedly inhibit the HSC proliferation. Additionally, Takeda G protein-coupled receptor 5 (TGR5) agonists induce the systemic release of glucagon-like peptides from intestinal L cells, which maintains glycemic homeostasis. This study assessed the combined effect of TGR5 agonist and DPP-4 inhibitor on diabetes-based liver fibrosis development. Male diabetic rats received intraperitoneal injection of porcine serum (PS) to induce liver fibrosis, and they were orally administered the following agents: oleanolic acid (OA) as a TGR5 agonist, anagliptin (ANA) as a DPP-4 inhibitor, and a combination of both agents. Treatment with OA or ANA significantly improved glycemic status and attenuated intrahepatic steatosis and lipid peroxidation in diabetic rats. PS-induced liver fibrosis development was also drastically suppressed by treatment with either agent, and the combination of both reciprocally enhanced the antifibrotic effect. Fecal microbiome demonstrated that both agents inhibited the increase in the Firmicutes/Bacteroidetes ratio, an indicator of dysbiosis related to metabolic syndromes. Furthermore, ANA directly inhibited in vitro HSC proliferative and profibrogenic activities. Collectively, TGR5 agonist and DPP-4 inhibitor appears to be a novel strategy against liver fibrosis under diabetic conditions.; 博士（医学）・甲第766号・令和3年3月15日; © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).; identifier:Cells Vol.8 No.10 Article No.1153 (2019 Sep); identifier:20734409; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/3890; identifier:Cells, 8(10): Article No.1153
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.3390/cells8101153
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU

Table of Contents

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3890/1/01%e7%94%b2766%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3890/2/02%e7%94%b2766%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3890/3/03%e7%94%b2766%e6%9c%ac%e6%96%87.pdf fulltext